AssetMark’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-123,492
| Closed | -$3.88M | – | 3792 |
|
|
2026
Q2 | $3.88M | Buy |
123,492
+21,056
| +21% | +$621K | 0.01% | 804 |
|
|
2026
Q1 | $2.54M | Buy |
102,436
+16,299
| +19% | +$388K | 0.01% | 827 |
|
|
2025
Q4 | $2.01M | Sell |
86,137
-3,172
| -4% | -$70.7K | ﹤0.01% | 852 |
|
|
2025
Q3 | $1.76M | Buy |
89,309
+12,669
| +17% | +$261K | ﹤0.01% | 851 |
|
|
2025
Q2 | $1.66M | Sell |
76,640
-6,596
| -8% | -$156K | ﹤0.01% | 807 |
|
|
2025
Q1 | $2.02M | Buy |
83,236
+12,434
| +18% | +$280K | 0.01% | 721 |
|
|
2024
Q4 | $1.48M | Sell |
70,802
-1,443
| -2% | -$31K | ﹤0.01% | 775 |
|
|
2024
Q3 | $1.44M | Buy |
72,245
+1,704
| +2% | +$31.6K | ﹤0.01% | 718 |
|
|
2024
Q2 | $1.09M | Buy |
70,541
+1,866
| +3% | +$29K | ﹤0.01% | 743 |
|
|
2024
Q1 | $1.09M | Buy |
68,675
+3,997
| +6% | +$60.2K | ﹤0.01% | 713 |
|
|
2023
Q4 | $1.09M | Buy |
64,678
+2,505
| +4% | +$34.2K | ﹤0.01% | 660 |
|
|
2023
Q3 | $727K | Buy |
62,173
+6,218
| +11% | +$83.2K | ﹤0.01% | 685 |
|
|
2023
Q2 | $752K | Sell |
55,955
-2,093
| -4% | -$30.1K | ﹤0.01% | 654 |
|
|
2023
Q1 | $962K | Buy |
58,048
+566
| +1% | +$9.34K | ﹤0.01% | 606 |
|
|
2022
Q4 | $1.07M | Sell |
57,482
-1,650
| -3% | -$25.4K | ﹤0.01% | 555 |
|
|
2022
Q3 | $759K | Buy |
+59,132
| New | +$701K | ﹤0.01% | 578 |
|
Other funds holding CPRX
AssetMark's CPRX Position: Q3 2026 in Review
AssetMark sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 123,492 shares — an estimated $3.88M sold.
AssetMark first reported a position in CPRX in Q3 2022 and held it in 16 quarters. The position peaked at $3.88M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- AssetMark reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- AssetMark sold 123,492 Catalyst Pharmaceutical shares in Q3 2026, an estimated $3.88M.
- AssetMark first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 16 quarters.
- AssetMark's Catalyst Pharmaceutical position peaked at $3.88M in Q2 2026.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.